MARKET

BIIB

BIIB

Biogen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

244.85
+0.76
+0.31%
Opening 15:37 12/04 EST
OPEN
244.86
PREV CLOSE
244.09
HIGH
248.96
LOW
244.13
VOLUME
729.20K
TURNOVER
--
52 WEEK HIGH
374.99
52 WEEK LOW
223.25
MARKET CAP
37.68B
P/E (TTM)
8.11
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
What Will Biogen Do If Its Alzheimer's Drug Goes South?
Investor's Business Daily · 8h ago
Psoriasis Drug Market 2020 – 2026: Historical Analysis, Growth Size, Positively Impact, Demand and Supply, Sales Revenue, Values, Price, Trends, Opportunity, Key Manufacture, Industry Share and Global Forecast
Heraldkeepers · 15h ago
New Coalition Aims To Close The Opportunity Gap In Bioscience
Liftstream, New England Venture Capital Association (NEVCA), Third Rock Ventures, Biogen Inc. (NASDAQ: BIIB) and BioDirector today announced Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion (DE&I) in the life sciences sector.
BusinessWire · 1d ago
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
Zacks · 2d ago
Look for Shares of Biogen Inc to Potentially Pullback after Yesterday's 2.42% Rise
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $245.04 to a high of $249.68. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $244.33 on volume of 807,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 2d ago
Biogen Inc Rises 2.42% on Heavy Volume: Watch For Potential Pullback
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $245.04 to a high of $249.68. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $244.33 on volume of 807,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 2d ago
Sage Therapeutics Draws Negative Commentary on Biogen Deal
Sage shares fell as two analysts offered negative assessments of its agreement with Biogen to work together on Sage's depression drug.
TheStreet.com · 3d ago
Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies
Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.
Zacks · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIIB. Analyze the recent business situations of Biogen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 34 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIIB stock price target is 291.40 with a high estimate of 450.00 and a low estimate of 175.00.
EPS
Institutional Holdings
Institutions: 1.54K
Institutional Holdings: 140.88M
% Owned: 91.55%
Shares Outstanding: 153.88M
TypeInstitutionsShares
Increased
304
4.22M
New
184
156.09K
Decreased
420
8.43M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.02%
Pharmaceuticals & Medical Research
+1.44%
Key Executives
Chairman/Independent Director
Stelios Papadopoulos
Chief Executive Officer/Director
Michel Vounatsos
Chief Financial Officer/Executive Vice President
Michael McDonnell
Chief Human Resource Officer/Executive Vice President
Ginger Gregory
Executive Vice President/Secretary
Susan Alexander
Executive Vice President
.. ..
Executive Vice President
Alphonse Galdes
Executive Vice President
Chirfi Guindo
Executive Vice President
Daniel Karp
Executive Vice President
Alfred Sandrock
Senior Vice President/Chief Information Officer
Mark Hernon
Chief Accounting Officer/Vice President
Robin Kramer
Independent Director
Alexander Denner
Independent Director
Caroline Dorsa
Independent Director
William Hawkins
Independent Director
Nancy Leaming
Independent Director
Jesus Mantas
Independent Director
Richard Mulligan
Independent Director
Robert Pangia
Independent Director
Brian Posner
Independent Director
Eric Rowinsky
Independent Director
Stephen Sherwin
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BIIB
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Biogen Inc stock information, including NASDAQ:BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.